Literature DB >> 3876759

The use of rest and exercise radionuclide ventriculography in risk stratification in patients with suspected coronary artery disease.

A S Iskandrian, A H Hakki, I P Goel, E D Mundth, S A Kane-Marsch, C L Schenk.   

Abstract

The study examined the value of rest and exercise radionuclide ventriculography in risk stratification in patients with suspected coronary artery disease. There were 604 patients, 474 men and 130 women, aged 55 +/- 11 years (mean +/- standard deviation). At a follow-up of 18 +/- 10 months, there were 43 hard cardiac events: 27 patients died of cardiac causes and 16 had nonfatal acute myocardial infarctions. Univariate and multivariate survival analysis of the 10 most important clinical and exercise variables identified the exercise left ventricular ejection fraction as the most important predictor of death and total cardiac events (chi 2 = 18.1 and 29.6, respectively). The exercise heart rate was a significant, independent, but much weaker predictor of cardiac death and total events (chi 2 = 8.4 and 3.9, respectively), while exercise tolerance was a significant independent predictor of cardiac death only (chi 2 = 6.4). Actuarial life table analysis showed that the risk for future cardiac events increased in stepwise fashion as the exercise ejection fraction decreased. Thus, the exercise left ventricular ejection fraction is a useful prognosticator in patients with suspected coronary artery disease. This finding has important implications in patient management.

Entities:  

Mesh:

Year:  1985        PMID: 3876759     DOI: 10.1016/0002-8703(85)90471-5

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  17 in total

1.  Does exercise radionuclide angiography still have a role in clinical cardiac assessment?

Authors:  A D Kelion; A P Banning; O J Ormerod
Journal:  J Nucl Cardiol       Date:  1999 Sep-Oct       Impact factor: 5.952

2.  Comparison between ECTb and QGS for assessment of left ventricular function from gated myocardial perfusion SPECT.

Authors:  Kenneth Nichols; Cesar A Santana; Russell Folks; Elizabeth Krawczynska; C David Cooke; Tracy L Faber; Steven R Bergmann; Ernest V Garcia
Journal:  J Nucl Cardiol       Date:  2002 May-Jun       Impact factor: 5.952

3.  Quantitative phase analysis of myocardial wall thickening by technetium-99m 2-methoxy-isobutyl-isonitrile SPECT.

Authors:  T Takeda; H Toyama; N Ishikawa; M Satoh; T Masuoka; R Ajisaka; K Iida; W Jin; Y Sugishita; Y Itai
Journal:  Ann Nucl Med       Date:  1992-05       Impact factor: 2.668

Review 4.  Nuclear medicine.

Authors:  P J Ell
Journal:  Postgrad Med J       Date:  1992-02       Impact factor: 2.401

5.  Assessment of ventricular function with first-pass radionuclide angiography using technetium 99m hexakis-2-methoxyisobutylisonitrile: a European multicentre study.

Authors:  G Bisi; R Sciagrà; U Büll; K E Britton; C Eilles; D Eissner; K Hahn; H Höffken; K Joseph; J H McKillop
Journal:  Eur J Nucl Med       Date:  1991

6.  The role of first-pass radionuclide angiography in the era of gated SPECT myocardial perfusion imaging.

Authors:  Rajesh Venkataraman; Jack Heo; Robert C Hendel; John J Mahmarian; Ami E Iskandrian
Journal:  J Nucl Cardiol       Date:  2008-09-07       Impact factor: 5.952

Review 7.  First-pass radionuclide angiocardiography with single-crystal gamma cameras.

Authors:  K Nichols; E G DePuey; A Rozanski
Journal:  J Nucl Cardiol       Date:  1997 Jan-Feb       Impact factor: 5.952

8.  Probability analysis in the diagnosis of coronary disease.

Authors:  R Underwood
Journal:  Br Med J (Clin Res Ed)       Date:  1986-01-04

9.  Evaluation of changes in myocardial perfusion and function on exercise in patients with coronary artery disease by gated MIBI scintigraphy.

Authors:  P Avery; N Hudson; P Hubner
Journal:  Br Heart J       Date:  1993-07

10.  Do patient data ever exceed the partial volume limit in gated SPECT studies?

Authors:  K Nichols; E G DePuey; M I Friedman; A Rozanski
Journal:  J Nucl Cardiol       Date:  1998 Sep-Oct       Impact factor: 5.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.